• Farnesyl Alcohol Azide and KRAS Phase Separation

  2026-10-10

  Farnesyl Alcohol Azide is examined in the context of emerging KRAS farnesylation biology. This article explains how condensate formation, RCE1 clustering, and membrane trafficking reshape interpretation of colorectal cancer research while clearly separating reported evidence from product-specific assumptions.

• Methotrexate Beyond DHFR: A Translational Lens

  2026-10-09

  Methotrexate is more than a dihydrofolate reductase inhibitor: its intracellular persistence, cell-state dependence, immunomodulatory effects, and membrane interactions create a multidimensional translational research problem. This article connects folate biology with biomimetic permeability models while distinguishing established findings from hypotheses that still require validation.

• Perphenazine: From D2 Antagonism to Host Defense

  2026-10-09

  Perphenazine is more than a dopamine D2 receptor antagonist: its receptor pharmacology provides a framework for interpreting mitochondrial, neuropharmacology, and host-directed immune findings. This article separates reported evidence from hypothesis and explains what recent phenothiazine research can—and cannot—establish.

• Neomycin Sulfate: Research Context and Evidence

  2026-10-08

  A source-grounded overview of neomycin sulfate in RNA/DNA structure interaction studies, ion-channel research, and microbiome-related experimental interpretation, with emphasis on evidence strength and limitations.

• Imatinib Hydrochloride Beyond Simple Kinase Blockade

  2026-10-08

  Imatinib hydrochloride offers a well-established framework for studying oncogenic kinase signaling, while emerging p38α–phosphatase research suggests a broader way to interpret kinase inhibition, conformational control, and translational evidence.

• Nonivamide: TRPV1 Signaling and Research Evidence

  2026-10-07

  A source-grounded overview of Nonivamide as a capsaicin analog, covering TRPV1 neuroimmune signaling, reported anti-inflammatory findings, cancer research claims, evidence strength, and key limitations.

• ML216 and the Next Era of DNA Repair Translation

  2026-10-07

  ML216 offers a useful framework for examining BLM-dependent DNA repair, sister chromatid exchange, and context-specific tumor vulnerability. Its translational value, however, depends on separating BLM biology from the WRN-centered findings reported in MSI colorectal cancer and on treating product potency as assay-context evidence rather than clinical proof.

• Doxorubicin: Research Context and Evidence Limits

  2026-10-06

  Doxorubicin, also known as Adriamycin, is a widely used anthracycline reference compound in cancer biology. This overview distinguishes supplier-described mechanisms from published clinical evidence, examines its historical relevance in small cell lung cancer, and outlines the limitations of extrapolating findings from topotecan studies to Doxorubicin.

• CCK-8 Suppresses IgG1 in Activated B Cells

  2026-10-06

  A 2011 study found that sulfated CCK-8 reduced proliferation and IgG1 production in lipopolysaccharide-activated mouse B cells, with evidence implicating CCK2R-linked regulation of differentiation-associated transcription factors. The work extends cholecystokinin biology into humoral immune regulation while remaining limited to an in vitro murine primary-cell model.

• EGFP sgRNA in HeLa: Evidence and Limits

  2026-10-05

  EGFP sgRNA in HeLa is best interpreted as a reporter-gene perturbation reagent, not as a validated editing outcome. The supplied dossier identifies three EGFP-targeting sgRNAs at 3 μmol each, while the available review supports multiplexed CRISPR–Cas as a framework that can produce indels, deletions, and structural variants but does not validate SKU R2997 performance.

• Talabostat mesylate: From DPP4 to CARD8

  2026-10-05

  Talabostat mesylate, also known as PT-100 or Val-boroPro, is more than a conventional FAP/DPP4 research tool. Emerging evidence links DPP inhibition to CARD8-dependent pyroptosis in resting human T cells, creating a translational framework that connects tumor stroma, peptide-processing enzymes, innate immune sensing, and context-dependent T-cell vulnerability.

• APOL1 Evolution, Isoforms, and APOL3 Interactions

  2026-10-04

  Khalaila and Skorecki integrate population genetics, APOL1 splice-isoform biology, and APOL1–APOL3 interaction evidence to refine models of APOL1-associated cellular injury. The paper does not resolve a single causal pathway for kidney disease, but it identifies haplotype context, isoform-specific behavior, and APOL3 binding as connected priorities for future mechanistic studies.

• Iptacopan: Interpreting Alternative Pathway Evidence

  2026-10-03

  Iptacopan (LNP023) is a selective, reversible factor B inhibitor that provides a focused way to study alternative complement pathway amplification. This evidence-led guide explains how biochemical, cellular, animal, and clinical findings should be interpreted without conflating pathway selectivity with complete complement blockade.

• 25-Hydroxycholesterol Drives AMPK–STAT6 in TAMs

  2026-10-01

  Xiao et al. identify CH25H-derived 25-hydroxycholesterol as an immunometabolic checkpoint that activates lysosomal AMPKα through a GPR155–mTORC1 mechanism and strengthens STAT6-dependent macrophage suppression. The study links this pathway to ARG1 production, reduced antitumor T-cell activity, and improved anti-PD-1 responses after CH25H targeting.

• DPF2 Splicing Rewires Chromatin in Neural Fate

  2026-10-01

  Nazim and colleagues show that PTBP1-regulated alternative splicing of DPF2 changes how BAF chromatin-remodeling complexes engage regulatory DNA during the transition from stem cells to neuronal progenitors. The work connects a defined exon switch with isoform-specific chromatin occupancy, transcription-factor associations, and neuronal differentiation phenotypes.

8688 records 1/580 page Next 12345 下5页 Last page